Lol. If you have the guts, tag and quote my post instead.
The ideal vaccine is still to prevent infections, not just deaths, so as to achieve herd immunity. Unfortunately, circumstances have changed for the worse. But even still, vaccines still have different efficacies and we're looking out for vaccines which can reduce mortality to the greatest extent even without preventing infection.
Because no current vaccine is effective in preventing delta infection, we have to fall back on looking at just mortality rates to determine which current vaccine can 'reduce mortality to the greatest extent'.
Also, delta is not the only variant around. Delta has not even hit Chile yet.
View attachment 767291
This page has a large number of charts on the pandemic. In the box below you can select any country you are interested in – or several, if you want to compare countries.
ourworldindata.org
You're selectively picking data, and you know that. What about the months before that?
Chile may have seen daily deaths fall in the past month, but it has not seen any significant reduction in deaths since inoculation started in January.
View attachment 767288
View attachment 767289
On the other hand, the UK has seen a significant reduction in deaths since its peak in January, despite the current uptick.
View attachment 767286
View attachment 767287
Chile's own real world study shows that there are indeed differences in vaccine efficacies.
Sinovac's COVID-19 vaccine was 58.5% effective in preventing symptomatic illness among millions of Chileans who received it between February and July, the Chilean health authorities said on Tuesday, while Pfizer's COVID-19 shot was 87.7% effective and AstraZeneca's was 68.7% effective.
www.reuters.com
SANTIAGO, Aug 3 (Reuters) - Sinovac's COVID-19 vaccine was 58.5% effective in preventing symptomatic illness among millions of Chileans who received it between February and July, the Chilean health authorities said on Tuesday, while Pfizer's COVID-19 shot was 87.7% effective and AstraZeneca's was 68.7% effective.
The data came in the latest "real world" data published by the Chilean authorities into the effectiveness among its population of a raft of COVID-19 vaccines.
Chile began one of the world's fastest inoculation campaigns against COVID-19 in December, having now fully vaccinated more than 60% of its population, predominantly with Sinovac's
(SVA.O)CoronaVac.
That vaccine was 86% effective in preventing hospitalization, 89.7% effective in preventing admission to intensive care units and 86% effective in preventing deaths within the population between February and July, health official Dr Rafael Araos said in a press conference on Tuesday.
In April, the same study found that CoronaVac was 67% effective in preventing symptomatic illness, 85% effective in preventing hospitalizations and 80% effective in preventing deaths, suggesting its capacity to prevent the more serious impacts of the virus has strengthened, while its capacity to stop symptomatic illness diminished.
Araos said a reduction in protection from vaccines was inevitable over time, particularly with the arrival and growing prevalence of more virulent strains such as the Delta variant.
"If Delta becomes more prevalent and the vaccine has a weaker response, we could observe a faster fall (in effectiveness)," he said, adding his voice to calls for a third, booster dose to be issued.
The government also published data on the effectiveness of other vaccines administered in Chile, made by Pfizer BioNTech
(PFE.N),
(22UAy.DE) and AstraZeneca
(AZN.L).
Pfizer's vaccine was 87.7% effective in preventing symptomatic COVID-19 in the same period, 98% effective in preventing intensive care admission and 100% effective in preventing death, Araos said.
AstraZeneca's was 68.7% effective in preventing symptomatic COVID-19 in the same period, 98% effective in preventing intensive care admissions and 100% effective in preventing death, Araos said.
Chile's study examined the vaccines' effectiveness among different cohorts of people who either received two doses of the specified vaccine, partial doses of the vaccine or no vaccine at all.
The CoronaVac part of the study examined a group of 8.6 million people, the Pfizer BioNTech part studied a group of 4.5 million people and the AstraZeneca part looked at a group of 2.3 million people.